Compare · MPLT vs NVO
MPLT vs NVO
Side-by-side comparison of MapLight Therapeutics Inc. (MPLT) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MPLT and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $220.35B.
- Over the past year, MPLT is up 63.0% and NVO is down 34.2% - MPLT leads by 97.2 points.
- MPLT has been more active in the news (15 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 7 for MPLT).
- Company
- MapLight Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $29.77+2.32%
- $41.18+6.93%
- Market cap
- -
- $220.35B
- 1M return
- +63.91%
- +13.32%
- 1Y return
- +62.97%
- -34.24%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 15
- 5
- Recent ratings
- 7
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest MPLT
- SEC Form 4 filed by Foff Erin Pennock
- SEC Form 4 filed by Lillie James Woodruff
- SEC Form 4 filed by Hanson Kristopher
- SEC Form 4 filed by Gillis Jonathan
- SEC Form 4 filed by Kreitzer Anatol
- SEC Form 4 filed by Setia Vishwas
- SEC Form 4 filed by Kroeger Christopher A.
- SEC Form 4 filed by Malenka Robert C.
- SEC Form 144 filed by MapLight Therapeutics Inc.
- Amendment: SEC Form 144/A filed by MapLight Therapeutics Inc.
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S